| Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium TGM Van Erp, DP Hibar, JM Rasmussen, DC Glahn, GD Pearlson, ... Molecular psychiatry 21 (4), 547-553, 2016 | 998 | 2016 |
| Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia E Damaraju, EA Allen, A Belger, JM Ford, S McEwen, DH Mathalon, ... NeuroImage: Clinical 5, 298-308, 2014 | 900 | 2014 |
| Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis Y Iturria-Medina, RC Sotero, PJ Toussaint, JM Mateos-Pérez, AC Evans Nature communications 7 (1), 11934, 2016 | 825 | 2016 |
| Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis T McGlashan, R Zipursky, D Perkins, J Addington, T Miller, S Woods, ... Am J Psychiatry 163 (5), 790-799, 2006 | 710 | 2006 |
| Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium TGM Van Erp, E Walton, DP Hibar, L Schmaal, W Jiang, DC Glahn, ... Biological psychiatry 84 (9), 644-654, 2018 | 538 | 2018 |
| Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group S Kelly, N Jahanshad, A Zalesky, P Kochunov, I Agartz, C Alloza, ... Molecular psychiatry 23 (5), 1261-1269, 2018 | 493 | 2018 |
| Plasma tau in Alzheimer disease N Mattsson, H Zetterberg, S Janelidze, PS Insel, U Andreasson, ... Neurology 87 (17), 1827-1835, 2016 | 392 | 2016 |
| The genetic architecture of the human cerebral cortex KL Grasby, N Jahanshad, JN Painter, L Colodro-Conde, J Bralten, ... Science 367 (6484), eaay6690, 2020 | 386 | 2020 |
| Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study SG Potkin, JA Turner, GG Brown, G McCarthy, DN Greve, GH Glover, ... Schizophrenia Bull 35 (1), 19-31, 2009 | 359 | 2009 |
| In vivo staging of regional amyloid deposition MJ Grothe, H Barthel, J Sepulcre, M Dyrba, O Sabri, SJ Teipel, ... Neurology 89 (20), 2031-2038, 2017 | 296 | 2017 |
| Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease S Palmqvist, H Zetterberg, N Mattsson, P Johansson, L Minthon, ... Neurology 85 (14), 1240-1249, 2015 | 283 | 2015 |
| A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly AJ Ho, JL Stein, X Hua, S Lee, DP Hibar, AD Leow, ID Dinov, AW Toga, ... Proc Natl Acad Sci USA 107 (18), 8404-8409, 2010 | 280 | 2010 |
| The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study … TH McGlashan, RB Zipursky, D Perkins, J Addington, TJ Miller, ... Schizophrenia Res 61 (1), 7-18, 2003 | 269 | 2003 |
| Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease DA Wolk, BC Dickerson, M Weiner, M Aiello, P Aisen, MS Albert, ... Proc Natl Acad Sci USA 107 (22), 10256-10261, 2010 | 249 | 2010 |
| Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE S Ayton, NG Faux, AI Bush Nature communications 6 (1), 6760, 2015 | 239 | 2015 |
| Subregional neuroanatomical change as a biomarker for Alzheimer's disease D Holland, JB Brewer, DJ Hagler, C Fennema-Notestine, AM Dale, ... Proc Natl Acad Sci USA 106 (49), 20954-20959, 2009 | 229 | 2009 |
| Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies GH Glover, BA Mueller, JA Turner, TGM Van Erp, TT Liu, DN Greve, ... Journal of Magnetic Resonance Imaging 36 (1), 39-54, 2012 | 218 | 2012 |
| Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology TW Schmitz, R Nathan Spreng Nature communications 7 (1), 13249, 2016 | 214 | 2016 |
| The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: II. Baseline … TJ Miller, RB Zipursky, D Perkins, J Addington, SW Woods, KA Hawkins, ... Schizophrenia Research 61 (1), 19-30, 2003 | 185 | 2003 |
| Vascular burden and Alzheimer disease pathologic progression RY Lo, WJ Jagust Neurology 79 (13), 1349-1355, 2012 | 169 | 2012 |
Daniel MathalonProfessor of Psychiatry, University of California San FranciscoVerified email at ucsf.edu
